University of Florida Research Foundation, Incorporated

University of Pennsylvania

Kempharm Consulting Inc.

Hong Xing

William Reade Kem

Ferenc Soti

Jon Lindstrom

Anne Rouchaud

Kristin Marie Andrud

Embodiments of the present disclosure provide for compounds such as those shown in FIG.(compounds A, B, C, and D), 2'substituted nicotine compounds, azetidine compounds, ether linked nicotine compounds (FIG., compounds E, F, G, and H), methods of synthesis of the compounds, methods of treatment of a condition using compounds A, B, C, D, 2&#x2032;substituted nicotine compounds, azetidine compounds, or ether linked nicotine compounds, methods of selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors, and the like. 

Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use

The invention relates to the design and synthesis of novel anabaseine-based compounds, which are useful in treating or preventing a wide variety of conditions, including nervous system diseases or disorders, such as, schizophrenia, Alzheimer's disease, Parkinson's disease, drug dependence, and substance addiction, and compositions, kits, and methods thereof. The invention also provides novel anabaseine-based compounds, compositions, kits, and methods thereof for treating or preventing non-nerve system diseases or disorders (such as, inflammation and cancer) in a subject identified in need thereof. Certain enantiomeric compounds of the invention exhibited enhanced selectivity toward &#x3b1;7 nAChRs relative to alpha4beta2 nAChRs. Other enantiomeric compounds of the invention exhibited enhanced selectivity for alpha4beta2 nAChRs relative to &#x3b1;7 nAChRs.

Nicotine receptor targeted compounds and compositions

Growing community of inventors

Gainesville, FL, United States of America

Hong Xing